Supernus Schedules Conference Call to Present Results of Phase IIb Clinical Trial of SPN-812 in Children with ADHD Read more about Supernus Schedules Conference Call to Present Results of Phase IIb Clinical Trial of SPN-812 in Children with ADHD
Supernus Receives FDA Tentative Approval for Expanded Label of Trokendi XR® to Include Migraine Prophylaxis in Adults Read more about Supernus Receives FDA Tentative Approval for Expanded Label of Trokendi XR® to Include Migraine Prophylaxis in Adults
Supernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III Elected Chairman Read more about Supernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III Elected Chairman
Supernus Announces Second Quarter 2016 Financial Results Read more about Supernus Announces Second Quarter 2016 Financial Results
Supernus to Host Second Quarter 2016 Earnings Conference Call Read more about Supernus to Host Second Quarter 2016 Earnings Conference Call
Supernus Announces Issuance of Seventh U.S. Patent Protecting Oxtellar XR® Read more about Supernus Announces Issuance of Seventh U.S. Patent Protecting Oxtellar XR®
Supernus Provides Update on Trokendi XR® Migraine sNDA and Reiterates Guidance Read more about Supernus Provides Update on Trokendi XR® Migraine sNDA and Reiterates Guidance
Supernus Announces Issuance of Sixth U.S. Patent Protecting Oxtellar XR® Read more about Supernus Announces Issuance of Sixth U.S. Patent Protecting Oxtellar XR®
Supernus to Present at June Jefferies Healthcare Conference Read more about Supernus to Present at June Jefferies Healthcare Conference
Supernus Enters Into Partial Settlement Agreement with Actavis on Oxtellar XR® Read more about Supernus Enters Into Partial Settlement Agreement with Actavis on Oxtellar XR®